Figure 2

Stratification analysis of the patients according to the oesophageal cancer stage showed the incorporation of an MDT significantly reduced death risk for patients with stages 2, 3, and 4 cancer; the reduction was particularly marked for patients with stage 3 cancer (HR = 0.72; 95% CI 0.67–0.79).